How couples answer one question shows whether they communicate well about money, Cornell research finds
https://www.cnbc.com/2024/06/24/why-couples-avoid-talking-about-financial-issues-and-how-to-change.html
Jun 24, 2024 - When it comes to financial issues, it helps for couples to talk it out. But new research from Cornell University finds many tend to do the opposite.
0
3 Financial Funds to Buy as Fed Projects One Rate Cut in 2024
https://www.zacks.com/stock/news/2292275/3-financial-funds-to-buy-as-fed-projects-one-rate-cut-in-2024?cid=CS-ZC-FT-mutual_fund_commentary-2292275
Jun 24, 2024 - Funds like FSLBX, RPFGX and FIDSX are expected to gain as the Fed is likely to keep interest rates higher for a longer period owing to stubbornly high inflation.
0
Visa: One Of The Best Dividend Growth Stocks Of All Time Is On Sale
https://seekingalpha.com/article/4700567-visa-one-of-the-best-dividend-growth-stocks-of-all-time-is-on-sale?source=feed
Jun 23, 2024 - Discover why Visa may be a better investment option than overpriced AI stocks, with strong growth potential and consistent dividends.
0
Rivian's Next Battle Is One You Wouldn't Expect
https://www.fool.com/investing/2024/06/23/rivians-next-battle-is-one-you-wouldnt-expect/?source=iedfolrf0000001
Jun 23, 2024 - Would it surprise you if Rivian's next battle came against tech companies? That's what a recent survey revealed.
0
3 Tiny Space Value Stocks: Which One Should You Buy?
https://www.fool.com/investing/2024/06/23/3-tiny-space-value-stocks-which-one-should-you-buy/?source=iedfolrf0000001
Jun 23, 2024 - Do you prefer growth stocks or value stocks? Buy space stocks, and you can have a bit of both.
0
Artificial Intelligence (AI) Juggernaut Nvidia Is One of the World's Most Valuable Companies. Here's What Investors Should Know.
https://www.fool.com/investing/2024/06/22/artificial-intelligence-ai-juggernaut-nvidia-is-no/?source=iedfolrf0000001
Jun 22, 2024 - Does Nvidia have a durable competitive moat, or is it only a temporary competitive advantage?
0
PBoC holds its one-year and five-year loan prime rates at 3.45% and 3.95%
https://seekingalpha.com/news/4117324-pboc-holds-its-one-year-and-five-year-loan-prime-rates-at-345-and-395?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
Jun 19, 2024 - The People's Bank of China ((PBoC)) left key lending rates unchanged at the June fixing, aligning with market expectations.
PBoC kept its one-year and five-year loan prime rates unchanged.
0
Lands' End (LE) Is Up 4.34% in One Week: What You Should Know
https://www.zacks.com/stock/news/2290576/lands-end-le-is-up-4-34-in-one-week-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_10-2290576
Jun 19, 2024 - Does Lands' End (LE) have what it takes to be a top stock pick for momentum investors? Let's find out.
0
Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up
https://www.zacks.com/stock/news/2290489/day-one-dawn-in-licenses-mabcare-cancer-candidate-stock-up?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2290489
Jun 19, 2024 - Day One (DAWN) gains 11% on in-licensing exclusive worldwide rights to MabCare???s MTX-13, which is set to begin clinical studies for adult and pediatric solid tumor indications.
0
Day One in licensing pact with MabCare for cancer therapy
https://seekingalpha.com/news/4117092-day-one-stock-licensing-deal-cancer-therapy?source=feed_sector_healthcare
Jun 18, 2024 - Day One Biopharmaceuticals (DAWN) stock gains as company signs a licensing agreement with MabCare for an experimental cancer therapy. Read more here.
0